Efficacy and Safety Study of CNTO 2476 in Participants With Visual Acuity Impairment Associated With Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD)

NCT02895815 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Company business decision

Conditions

Visual Acuity
Geographic Atrophy
Macular Degeneration

Interventions

COMBINATION_PRODUCT: CNTO 2476 (6.0 * 10^4 cells)
COMBINATION_PRODUCT: CNTO 2476 (3.0 * 10^5 cells)

Sponsor

Janssen Pharmaceutical K.K.